Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Federal Trade Commission
Queensland Health
Deloitte
Citi
Julphar
Boehringer Ingelheim
Mallinckrodt
Cantor Fitzgerald

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,410,102

« Back to Dashboard

Which drugs does patent 8,410,102 protect, and when does it expire?

Patent 8,410,102 protects MIRVASO and is included in one NDA.

This patent has sixty-four patent family members in twenty-four countries.
Summary for Patent: 8,410,102
Title:Methods and compositions for treating or preventing erythema
Abstract: Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one .alpha.-adrenergic receptor agonist and a pharmaceutically acceptable carrier.
Inventor(s): Graeber; Michael (Lawrenceville, NJ), Loesche; Christian (Valbonne, FR), Freidenreich; Philip (Yardley, PA), Dejovin; Jack A. (New Brunswick, NJ), Dejovin; Isabelle Jean (New Brunswick, NJ), Liu; Yin-Sang (Princeton Junction, NJ), Leoni; Matthew James (Hampton, NJ)
Assignee: Galderma Laboratories Inc. (Fort Worth, TX)
Application Number:13/072,104
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,410,102
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,410,102

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs Lp MIRVASO brimonidine tartrate GEL;TOPICAL 204708-001 Aug 23, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,410,102

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,859,551 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders ➤ Sign Up
8,231,885 Compounds, formulations, and methods for ameliorating telangiectasis ➤ Sign Up
8,586,586 Methods and compositions for treating or preventing erythema ➤ Sign Up
7,439,241 Compounds, formulations, and methods for treating or preventing rosacea ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Accenture
US Department of Justice
Chinese Patent Office
McKinsey
Moodys
Cerilliant
Teva
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.